Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation

Cancer Imaging. 2024 Jul 1;24(1):82. doi: 10.1186/s40644-024-00724-5.

Nabeel Mansour¹, Kathrin Heinrich^{2

3}, Danmei Zhang^{2

3

4}, Michael Winkelmann¹, Maria Ingenerf¹, Lukas Gold¹, Konstantin Klambauer¹, Martina Rudelius⁵, Frederick Klauschen⁵, Michael von Bergwelt-Baildon^{2

3

4}, Jens Ricke¹, Volker Heinemann^{2

3}, C Benedikt Westphalen^{2

3}, Wolfgang G Kunz^{6

7}

¹ Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
² Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
³ Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany.
⁴ German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany.
⁵ Institute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
⁶ Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. [email protected].
⁷ Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany. [email protected].

No abstract available

Publication types